NeuroSense Therapeutics Management
Management criteria checks 2/4
NeuroSense Therapeutics' CEO is Alon Ben-Noon, appointed in Jan 2016, has a tenure of 8.83 years. total yearly compensation is $1.01M, comprised of 36.2% salary and 63.8% bonuses, including company stock and options. directly owns 15.83% of the company’s shares, worth $2.77M. The average tenure of the management team and the board of directors is 2.8 years and 2.9 years respectively.
Key information
Alon Ben-Noon
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 36.2% |
| CEO tenure | 8.8yrs |
| CEO ownership | 15.8% |
| Management average tenure | 2.8yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely
Mar 22
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?
Dec 06Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Mar 03Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Nov 17NeuroSense Therapeutics GAAP EPS of -$0.55
Aug 31We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
Jul 06NeuroSense climbs 66% after early data supporting Alzheimer’s candidate
Jun 30Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?
Mar 31NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans
Mar 22NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases
Dec 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$13m |
| Dec 31 2023 | US$1m | US$367k | -US$10m |
| Sep 30 2023 | n/a | n/a | -US$11m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$2m | US$410k | -US$10m |
Compensation vs Market: Alon's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD650.80K).
Compensation vs Earnings: Alon's compensation has been consistent with company performance over the past year.
CEO
Alon Ben-Noon (45 yo)
8.8yrs
Tenure
US$1,013,000
Compensation
Mr. Alon Ben-Noon is the Co-Founder of NeuroSense Therapeutics Ltd. and serves as its Chief Executive Officer since 2016 and Director since February 2017. Mr. Ben-Noon served as Chair of Board of Directors...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.8yrs | US$1.01m | 15.83% $ 2.8m | |
| Chief Financial Officer | 3.4yrs | US$1.02m | 2.36% $ 414.0k | |
| Chief Operation Officer | no data | US$266.62k | 0.11% $ 19.8k | |
| Chief Technology Officer | 1.5yrs | US$291.62k | 0.34% $ 58.9k | |
| Chief Medical Officer | 2.9yrs | US$918.00k | 0.63% $ 110.7k | |
| VP of Quality & Compliance | 2.8yrs | no data | no data | |
| Head of HR | 1.4yrs | no data | no data | |
| C.R.A. | 1.8yrs | no data | no data |
2.8yrs
Average Tenure
45.5yo
Average Age
Experienced Management: NRSN's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | US$1.01m | 15.83% $ 2.8m | |
| Independent Chairman of the Board | 3.1yrs | US$1.48m | 0.33% $ 57.6k | |
| Independent External Director | 2.9yrs | US$104.00k | 0.12% $ 21.6k | |
| Independent External Director | 2.9yrs | US$104.00k | 0.12% $ 21.6k | |
| Chair of Scientific Advisory Board | no data | no data | no data | |
| Director | 2.8yrs | US$91.00k | 0.15% $ 25.7k | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data |
2.9yrs
Average Tenure
56yo
Average Age
Experienced Board: NRSN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.